论文部分内容阅读
目的 检测人表皮生长因子受体Ⅱ (HER2 /neu)与拓扑异构酶 (TOPOⅡα)在乳腺癌组织中的表达 ,探讨二者的相关关系及在乳腺癌临床化疗中的潜在价值。方法 采用RT -PCR和免疫组织化学方法分别检测 2 4例乳腺癌组织和相应的癌旁组织的HER2、TOPOⅡα的转录和蛋白质水平的表达。结果 RT -PCR结果显示 ,乳腺癌组织中HER2和TOPOⅡα阳性率分别是 2 9% ( 7/2 4)和 92 % ( 2 2 / 2 4) ,明显高于癌旁组织 [4 % ( 1/ 2 4)和 2 1% ( 5 / 2 4) ,P <0 0 0 1] ;免疫组化检测癌组织发现HER2和TOPOⅡα的表达率分别为 3 0 % ( 6/ 2 0 )和 94% ( 16/ 17) ,与RT -PCR结果一致 ,且 6例HER2表达阳性的组织中TOPOⅡα表达均为阳性 ,二者的表达相关 ,R =0 5 2 4,P <0 0 0 1。结论 HER2和TOPOⅡα在乳腺癌组织比癌旁组织有明显增加的表达率 ,且两基因的表达相关 ,提示两基因表达的上调在乳腺癌的发生及恶性表型维持中可能起一定作用。
Objective To detect the expression of human epidermal growth factor receptor Ⅱ (HER2 / neu) and topoisomerase (TOPOⅡα) in breast cancer tissues and to explore the relationship between the two and the potential value in the clinical chemotherapy of breast cancer. Methods RT-PCR and immunohistochemistry were used to detect the transcription and protein expression of HER2 and TOPOⅡα in 24 breast cancer tissues and corresponding paracancerous tissues respectively. Results The RT-PCR results showed that the positive rates of HER2 and TOPOⅡα in breast cancer tissues were 29% (7/2 4) and 92% (22/22) respectively, which were significantly higher than those in paracancerous tissues [4% (1 / The expression rates of HER2 and TOPOⅡα in cancer tissue were 30% (6/20) and 94% (2/20), respectively 16/17), which was consistent with RT-PCR. TOPOⅡα expression was positive in 6 cases with positive HER2 expression, the expression of which was correlated with R = 0 5 2 4, P 0 01 0. Conclusion The expression of HER2 and TOPOⅡα in breast cancer tissues is significantly higher than that in paracancerous tissues, and the expression of both genes is correlated. It suggests that the upregulation of both genes may play a role in the occurrence of breast cancer and the maintenance of malignant phenotype.